News
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced a $270 million acquisition of Inozyme Pharma, aiming to expand its rare ...
Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback